Progyny, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Progyny, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 21.1 times. Higher than 97% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 56.4 times by its yearly operating cash. Higher than 96% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $331 of operating cash. Higher than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$331Over the last 3 years, every $100 of reported profit came with $331 of operating cash.
Higher than 88% of Healthcare companies in United States.
Self-Funding Ratio
21.1×Over the last 3 years its own operating cash covered its investment spending (capex) 21.1 times.
Higher than 97% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$6Sales grew 64% in 3 years; of every extra $100 of sales, $6 became extra profit.
Lower than 61% of Healthcare companies in United States.
Asset Productivity Ratio
+64% / +37%In 3 years sales changed by +64% while total assets changed by +37%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
56.4×Debt due within a year is covered 56.4 times by its yearly operating cash.
Higher than 96% of Healthcare companies in United States.
Cash Cushion Ratio
+13%Cash, after subtracting all debt, equals 13% of its market value (net cash).
Higher than 54% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 78% of Healthcare companies in United States.
Tangible Net Worth Ratio
95%Of every $100 of net worth, $95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 80% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Progyny, Inc. owes $0.37 for every $1 it owns. Net profit rose 8% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
31.7Investors pay $31.7 for every $1 of Progyny, Inc.'s yearly profit, higher than 58% of Healthcare companies in United States.
P/B ratio
4.93The share price is 4.93 times Progyny, Inc.'s book value per share, higher than 72% of Healthcare companies in United States.
Market cap
$2.2 BThe total market value of all of Progyny, Inc.'s shares at today's price (share price × number of shares), larger than 77% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$453 MWhat Progyny, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.91Net worth divided by the number of shares. The share price of $29.12 is 4.9 times this, which is the P/B above.
Return on equity (ROE)
16.2%Progyny, Inc. earned 16.2% on its shareholders' money over the last year, higher than 88% of Healthcare companies in United States.
Owes vs Owns
0.37×Progyny, Inc. owes $0.37 for every $1 it owns (low), lower than 54% of Healthcare companies in United States.
Dividend yield
NoneProgyny, Inc. does not currently pay a dividend.
Revenue growth
+10%Revenue rose 10% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Profit growth
+8%Net profit rose 8% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Profit margin
4.5%Progyny, Inc. keeps $5 of every $100 of revenue as net profit.
Cash quality
3.6×Cash from Progyny, Inc.'s business was 3.6× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashProgyny, Inc. held $282 M more cash than debt (net cash) at Dec 2025.
Questions
What is Progyny, Inc.'s P/E ratio?
Investors pay $31.7 for every $1 of Progyny, Inc.'s yearly profit, higher than 58% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Progyny, Inc.: $2.2 B ÷ $453 M (30 Jun 2026) = 4.9.
What is Progyny, Inc.'s return on equity?
Progyny, Inc. earned 16.2% on its shareholders' money over the last year, higher than 88% of Healthcare companies in United States.
How much does Progyny, Inc. owe compared with what it owns?
Progyny, Inc. owes $0.37 for every $1 it owns (low), lower than 54% of Healthcare companies in United States.
Does Progyny, Inc. pay a dividend?
No. Progyny, Inc. does not currently pay a dividend.
Is Progyny, Inc.'s revenue growing?
Revenue rose 10% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.